A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration

Hepatology. 2009 Apr;49(4):1395-6; author reply 1396. doi: 10.1002/hep.22863.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Drug Therapy, Combination
  • Hepacivirus / genetics*
  • Hepatitis C / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Polyethylene Glycols / administration & dosage*
  • Randomized Controlled Trials as Topic
  • Recombinant Proteins
  • Ribavirin / administration & dosage*

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a